Free Trial
LON:STX

Shield Therapeutics (STX) Share Price, News & Analysis

Shield Therapeutics logo
GBX 7.60 -0.25 (-3.18%)
As of 10/17/2025 12:23 PM Eastern

About Shield Therapeutics Stock (LON:STX)

Advanced

Key Stats

Today's Range
7.40
8
50-Day Range
4.54
9
52-Week Range
2.10
9.10
Volume
1.28 million shs
Average Volume
2.75 million shs
Market Capitalization
£80.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
GBX 15
Consensus Rating
Buy

Company Overview

Shield Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
24th Percentile Overall Score

STX MarketRank™: 

Shield Therapeutics scored higher than 24% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Shield Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Upside Potential

    Shield Therapeutics has a consensus price target of GBX 15, representing about 97.4% upside from its current price of GBX 7.60.

  • Amount of Analyst Coverage

    Shield Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Shield Therapeutics' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Shield Therapeutics is -380.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Shield Therapeutics is -380.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Shield Therapeutics has a P/B Ratio of 138.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for STX.
  • Dividend Yield

    Shield Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Shield Therapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for STX.
  • Search Interest

    118 people have searched for STX on MarketBeat in the last 30 days. This is an increase of 71% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Shield Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Shield Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.04% of the stock of Shield Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 6.66% of the stock of Shield Therapeutics is held by institutions.

  • Read more about Shield Therapeutics' insider trading history.
Receive STX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Shield Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

STX Stock News Headlines

Claim Your Share of $5.39 BILLION in AI Equity Checks
The U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enforcing that means a $5.39 billion pot must be paid out to everyday Americans. See, virtually every AI model is built off stolen data...tc pixel
See More Headlines

STX Stock Analysis - Frequently Asked Questions

Shield Therapeutics' stock was trading at GBX 2.70 at the beginning of 2025. Since then, STX stock has increased by 181.5% and is now trading at GBX 7.60.

Shield Therapeutics plc (LON:STX) posted its quarterly earnings results on Thursday, April, 24th. The company reported ($3.00) EPS for the quarter. Shield Therapeutics had a negative trailing twelve-month return on equity of 470.50% and a negative net margin of 173.43%.

Shares of STX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that Shield Therapeutics investors own include AcelRx Pharmaceuticals (ACRX), Rockwell Medical (RMTI), AstraZeneca (AZN), Model N (MODN), Cara Therapeutics (CARA), Caladrius Biosciences (CLBS) and Cellectis (CLLS).

Company Calendar

Last Earnings
4/24/2025
Today
10/19/2025

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
Computer Hardware
Current Symbol
LON:STX
CIK
N/A
Fax
N/A
Employees
40,000
Year Founded
N/A

Price Target and Rating

High Price Target
GBX 15
Low Price Target
GBX 15
Potential Upside/Downside
+97.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Trailing Twelve Months)
GBX (0.02)
Trailing P/E Ratio
N/A
Forward P/E Ratio
107.40
P/E Growth
N/A
Net Income
-£36.28 million
Net Margins
-173.43%
Pretax Margin
N/A
Return on Equity
-470.50%
Return on Assets
-47.85%

Debt

Debt-to-Equity Ratio
3,691.50
Current Ratio
1.05
Quick Ratio
2.16

Sales & Book Value

Annual Sales
£41.50 million
Price / Sales
1.94
Cash Flow
GBX 1.19 per share
Price / Cash Flow
6.36
Book Value
GBX 0.05 per share
Price / Book
138.88

Miscellaneous

Outstanding Shares
1,061,803,000
Free Float
N/A
Market Cap
£80.70 million
Optionable
Not Optionable
Beta
1.42
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (LON:STX) was last updated on 10/19/2025 by MarketBeat.com Staff
From Our Partners